Startseite Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine

  • Sheikh Shoib , Madhulika Kotra , Sana Javed , Vinh-Son Nguyen und Barikar C. Malathesh ORCID logo EMAIL logo
Veröffentlicht/Copyright: 15. Juli 2022
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Esketamine, which is an S-enantiomer of ketamine, is better than conventional antidepressants and even better than R-ketamine. This article discusses the mechanism of action of Esketamine, how different it is from other antidepressants, its side effect profile, indications for use, various routes of administration and the review of existing literature on Esketamine.


Corresponding author: Barikar C. Malathesh, MD, PDF (Forensic Psyc), Department of Psychiatry, AIIMS –Bibinagar, Hyderabad, Telangana, India, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not Applicable.

  5. Ethical approval: Not applicable.

References

1. Bahr, R, Lopez, A, Rey, JA. Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T 2019;44:340–75.Suche in Google Scholar

2. Murrough, JW. Ketamine for depression: an update. Biol Psychiatr 2016;80:416–8. https://doi.org/10.1016/j.biopsych.2016.07.005.Suche in Google Scholar PubMed

3. Molero, P, Ramos-Quiroga, JA, Martin-Santos, R, Calvo-Sánchez, E, Gutiérrez-Rojas, L, Meana, JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs 2018;32:411–20. https://doi.org/10.1007/s40263-018-0519-3.Suche in Google Scholar PubMed

4. Turner, EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatr 2019;6:977–9. https://doi.org/10.1016/s2215-0366(19)30394-3.Suche in Google Scholar PubMed

5. Salahudeen, MS, Wright, CM, Peterson, GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf 2020;11:2042098620937899. https://doi.org/10.1177/2042098620937899.Suche in Google Scholar PubMed PubMed Central

6. Yang, C, Ren, Q, Qu, Y, Zhang, JC, Ma, M, Dong, C, et al.. Mechanistic target of rapamycin-independent antidepressant effects of (R)-Ketamine in a social defeat stress model. Biol Psychiatr 2018;83:18–28. https://doi.org/10.1016/j.biopsych.2017.05.016.Suche in Google Scholar PubMed

7. Paul, R, Schaaff, N, Padberg, F, Möller, HJ, Frodl, T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatr 2009;10:241–4. https://doi.org/10.1080/15622970701714370.Suche in Google Scholar PubMed

8. Correia-Melo, FS, Leal, GC, Vieira, F, Jesus-Nunes, AP, Mello, RP, Magnavita, G, et al.. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord 2020;264:527–34. https://doi.org/10.1016/j.jad.2019.11.086.Suche in Google Scholar PubMed

9. Singh, JB, Fedgchin, M, Daly, E, Xi, L, Melman, C, Bruecker, GD, et al.. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatr 2016;80:424–31. https://doi.org/10.1016/j.biopsych.2015.10.018.Suche in Google Scholar PubMed

10. Kaur, U, Pathak, BK, Singh, A, Chakrabarti, SS. Esketamine: a glimmer of hope in treatment-resistant depression. Eur Arch Psychiatr Clin Neurosci 2021;271:417–29. https://doi.org/10.1007/s00406-019-01084-z.Suche in Google Scholar PubMed

11. Mihaljević, S, Pavlović, M, Reiner, K, Ćaćić, M. Therapeutic mechanisms of ketamine. Psychiatr Danub 2020;32:325–33. https://doi.org/10.24869/psyd.2020.325.Suche in Google Scholar PubMed

12. Janssenlable. Spravato (esketamine) Nasal Spray [Internet]; 2020. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf [Accessed 17 Jul 2021].Suche in Google Scholar

13. Daly, EJ, Singh, JB, Fedgchin, M, Cooper, K, Lim, P, Shelton, RC, et al.. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatr 2018;75:139–48. https://doi.org/10.1001/jamapsychiatry.2017.3739.Suche in Google Scholar PubMed PubMed Central

14. Findeis, H, Sauer, C, Cleare, A, Bauer, M, Ritter, P. Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology (Berl) 2020;237:3295–302. https://doi.org/10.1007/s00213-020-05611-y.Suche in Google Scholar PubMed PubMed Central

15. Katz, EG, Hough, D, Doherty, T, Lane, R, Singh, J, Levitan, B. Benefit-risk assessment of esketamine nasal spray vs. Placebo in treatment-resistant depression. Clin Pharmacol Ther 2021;109:536–46. https://doi.org/10.1002/cpt.2024.Suche in Google Scholar PubMed PubMed Central

16. Popova, V, Daly, EJ, Trivedi, M, Cooper, K, Lane, R, Lim, P, et al.. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatr 2019;176:428–38. https://doi.org/10.1176/appi.ajp.2019.19020172.Suche in Google Scholar PubMed

17. Doherty, T, Wajs, E, Melkote, R, Miller, J, Singh, JB, Weber, MA. Cardiac safety of esketamine nasal spray in treatment-resistant depression: results from the clinical development program. CNS Drugs 2020;34:299–310. https://doi.org/10.1007/s40263-020-00699-4.Suche in Google Scholar PubMed PubMed Central

18. Khorassani, F, Talreja, O. Intranasal esketamine: a novel drug for treatment-resistant depression. Am J Health Syst Pharm 2020;77:1382–8. https://doi.org/10.1093/ajhp/zxaa191.Suche in Google Scholar PubMed

19. Canuso, CM, Singh, JB, Fedgchin, M, Alphs, L, Lane, R, Lim, P, et al.. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatr 2018;175:620–30. https://doi.org/10.1176/appi.ajp.2018.17060720.Suche in Google Scholar PubMed

20. Kim, J, Farchione, T, Potter, A, Chen, Q, Temple, R. Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class. N Engl J Med 2019;381:1–4. https://doi.org/10.1056/nejmp1903305.Suche in Google Scholar PubMed

21. Ionescu, DF, Fu, DJ, Qiu, X, Lane, R, Lim, P, Kasper, S, et al.. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol 2021;24:22–31. https://doi.org/10.1093/ijnp/pyaa068.Suche in Google Scholar PubMed PubMed Central

22. Morrison, RL, Fedgchin, M, Singh, J, Van Gerven, J, Zuiker, R, Lim, KS, et al.. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl) 2018;235:1107–19. https://doi.org/10.1007/s00213-018-4828-5.Suche in Google Scholar PubMed PubMed Central

23. Wang, J, Wang, Y, Xu, X, Peng, S, Xu, F, Liu, P. Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Med Sci Monit 2020;26:e922028-1–6.10.12659/MSM.922028Suche in Google Scholar PubMed PubMed Central

24. Smith-Apeldoorn, SY, Veraart, JKE, Kamphuis, J, van Asselt, ADI, Touw, DJ, Aan Het Rot, M, et al.. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. BMC Psychiatr 2019;19:375. https://doi.org/10.1186/s12888-019-2359-1.Suche in Google Scholar PubMed PubMed Central

25. Bahji, A, Vazquez, GH, Zarate, CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 2021;278:542–55. https://doi.org/10.1016/j.jad.2020.09.071.Suche in Google Scholar PubMed PubMed Central

26. Courtenay, AJ, McAlister, E, McCrudden, MTC, Vora, L, Steiner, L, Levin, G, et al.. Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery. J Contr Release 2020;322:177–86. https://doi.org/10.1016/j.jconrel.2020.03.026.Suche in Google Scholar PubMed PubMed Central

27. Fedgchin, M, Trivedi, M, Daly, EJ, Melkote, R, Lane, R, Lim, P, et al.. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 2019;22:616–30. https://doi.org/10.1093/ijnp/pyz039.Suche in Google Scholar PubMed PubMed Central

28. McIntyre, RS, Carvalho, IP, Lui, LMW, Majeed, A, Masand, PS, Gill, H, et al.. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord 2020;276:576–84. https://doi.org/10.1016/j.jad.2020.06.050.Suche in Google Scholar PubMed

29. McGirr, A, Berlim, MT, Bond, DJ, Neufeld, NH, Chan, PY, Yatham, LN, et al.. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. J Psychiatr Res 2015;62:23–30. https://doi.org/10.1016/j.jpsychires.2015.01.003.Suche in Google Scholar PubMed

30. Fu, DJ, Ionescu, DF, Li, X, Lane, R, Lim, P, Sanacora, G, et al.. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatr 2020;81:0.10.4088/JCP.19m13191Suche in Google Scholar PubMed

31. Pereira, S, Brennan, E, Patel, A, Moran, M, Wallier, J, Liebowitz, MR. Managing dissociative symptoms following the use of esketamine nasal spray: a case report. Int Clin Psychopharmacol 2021;36:54–7. https://doi.org/10.1097/yic.0000000000000327.Suche in Google Scholar PubMed PubMed Central

32. Daly, EJ, Trivedi, MH, Janik, A, Li, H, Zhang, Y, Li, X, et al.. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatr 2019;76:893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189.Suche in Google Scholar PubMed PubMed Central

33. Jonkman, K, van Rijnsoever, E, Olofsen, E, Aarts, L, Sarton, E, van Velzen, M, et al.. Esketamine counters opioid-induced respiratory depression. Br J Anaesth 2018;120:1117–27. https://doi.org/10.1016/j.bja.2018.02.021.Suche in Google Scholar PubMed

Received: 2021-11-29
Accepted: 2022-05-23
Published Online: 2022-07-15

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Letter to the Editor
  3. COVID-19 pandemic: transmission of SARS-CoV-2 in animals, a risk for human beings
  4. Original Articles
  5. Anti Mullerian hormone as a diagnostic tool for polycystic ovary syndrome in women of reproductive age with morbid obesity
  6. Potential tumor marker for hepatocellular carcinoma identification: PI3K and pro-inflammatory cytokines (TGF-β, IL-1, and IL-6)
  7. The investigation of the frequency of the alpha-1-antitrypsin phenotype in patients with liver cirrhosis
  8. Anti-oxidant effect of metformin through AMPK/SIRT1/PGC-1α/SIRT3– independent GPx1 expression in the heart of mice with endometriosis
  9. Hypoxia-inducible factor-1α and ischemia-modified albumin levels in intensive care COVID-19 Patients
  10. Association between TP53 Arg72Pro variant and recurrent pregnancy loss in the Greek population
  11. Selective estrogen receptor α and β antagonist aggravate cardiovascular dysfunction in type 2 diabetic ovariectomized female rats
  12. Adrenocorticotropic hormone (ACTH) level and adrenal deficiency in patients with mucocutaneous pemphigus
  13. The effect of resistance training on serum levels of sex hormones and sperm quality in male rats under X-ray radiation
  14. The effect of high-intensity interval training on serum and adipose tissues vaspin levels in rats fed a high-fat high-sucrose diet
  15. Anti-migratory effect of curcumin on A-549 lung cancer cells via epigenetic reprogramming of RECK/ matrix metalloproteinase axis
  16. Efficacy of rectal progesterone on maternal and neonatal outcomes in pregnant women with Preterm Premature Rupture of membranes: a triple-blind randomised clinical trial
  17. Case Report
  18. Ovarian tissue cryopreservation in Malaysia: a case series
  19. Review Articles
  20. An overview of prognostic value of neurologic and cardiac biomarkers in patients with COVID-19 sequelae
  21. Potential role of melatonin in prevention and treatment of lung cancer
  22. Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
Heruntergeladen am 7.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/hmbci-2021-0099/html
Button zum nach oben scrollen